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BACKGROUND: This study investigated the synergistic effect of sunitinib and rapamycin on tumor growth and
metastasis in murine breast cancer model.METHODS: The synergistic antitumor effect of sunitinib and rapamycin
on tumor growth and metastasis was investigated. Myeloid-derived suppressor cells (MDSCs) in spleens and
lungs were assessed. Tumor hypoxia, vessel density and micrometastasis were evaluated. Versican, indoleamine
2,3-dioxygenase (IDO), arginase 1, interleukin-6 (IL-6), IL-10, and transforming growth factor β (TGF-β) in the lungs
and tumors were examined. IL-6 and TGF-β in the blood were evaluated. RESULTS: Synergism between sunitinib
and rapamycin on tumor growth was observed. Sunitinib plus rapamycin reduced splenomegaly, MDSCs in
spleens and lungs, and microvessel density in tumor microenvironment, while exacerbated hypoxia and promoted
cancer lung metastasis. Sunitinib plus rapamycin markedly induced versican, IDO, arginase 1, IL-6, and TGF-β
expression in the lungs, whereas it reduced IDO and IL-10 expression in the primary tumor tissues. IL-6 levels in
the circulation were increased after rapamycin and combination therapies. CONCLUSIONS: The combination of
sunitinib plus rapamycin reduced the tumor growth but promoted tumor metastasis. This study warrants that
further mTOR inhibition treatment should be closely watched in clinical setting, especially combined with
antiangiogenic therapy.
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Angiogenesis is essential for tumor growth and progression [1].
Antiangiogenic therapies have been demonstrated effective on the
suppression of tumor growth [2]. Paradoxically, antiangiogenic
strategies can also induce local and distant metastasis [3]. Reduced
oxygen supply leads to the stabilization and activation of the
transcription factor hypoxia-induced factor 1 (HIF-1) [4]. Hypoxia
and the expression of HIF-1 are correlated with cancer metastasis and
unfavorable prognosis [5]. Through activation of the Twist, hypoxia
induces epithelial-to-mesenchymal transition [6], which was associ-
ated with cancer metastasis [7]. Sunitinib is one type of multitargeted
tyrosine kinase inhibitor, which targets several receptor tyrosine
kinases, including vascular endothelial growth factor receptor
(VEGFR) (VEGFR-1, VEGFR-2, and VEGFR-3), PDGFR
(PDGFR-α and PDGFR-β), and stem cell factor receptor (KIT)
[8]. Sunitinib monotherapy has activity in advanced breast cancers
[9]. Sunitinib has also been demonstrated to be effective incombination with chemotherapy in preclinical models [10].
However, sunitinib therapy can induce intratumoral hypoxia,
which enriches cancer stem cells [11].
The mammalian target of rapamycin (mTOR) promotes cell
growth, proliferation, and survival in response to nutrient signals and a
variety of cytokines. mTOR also plays a vital role in the regulation of
cancer cell growth and progression [12]. mTOR promotes cancer cell
migration and invasion [13]. mTOR has been demonstrated to impact
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signaling pathway is the downstream of VEGF and promotes
endothelial cell survival [14]. In the hind limb ischemia, Akt is
critical for ischemia and VEGF-induced angiogenesis [15]. Endothe-
lial cells in the tumor microenvironment have chronic Akt activation,
and the sustained Akt activation induces the formation of abnormal
microvessels, which mimic the effects of VEGF-A–induced angio-
genesis [16]. Treatment of cultured cells with rapamycin decreased
activation of Akt [17]. Rapamycin can inhibit pathologic angiogenesis
through the inhibition of endothelial Akt signaling [16] and VEGF
production [18]. Then, mTOR has been considered as a promising
target for cancer therapy [19].
mTOR regulates the expression of HIF-1α expression [20]. We
then hypothesized that rapamycin could suppress antiangiogenic
therapy–induced cancer metastasis. In addition, there is no study
investigating the synergism between antiangiogenic therapy and
rapamycin on breast tumor model. In our present study, we
demonstrate the synergistic effect of rapamycin and sunitinib on
tumor regression. However, the hypothesized therapeutic effect of
sunitinib combined with rapamycin on lung metastasis was not
observed, and, unexpectedly, we found that the combination
promoted the lung metastasis of cancer cells.
Materials and Methods
Mice
BALB/c mice (6-8 weeks old) were purchased from Beijing HFK
Bioscience Co (Beijing, China) and maintained under pathogen-free
conditions in the animal facility with individual ventilation. All animal
experiments were carried out according to protocols approved by
Sichuan University’s Institutional Animal Care and Use Committee.
Cell Lines and Reagents
Murine breast cancer cell lines (4T1) were cultured in the
RPMI1640 media supplemented with 10% FBS at 37°C, 5% CO2
atmosphere. Rapamycin was obtained from Selleck Chemicals
(Houston, TX). Sunitinib was purchased from Pfizer company
(New York, NY).
Tumor Challenge and Treatment
Syngeneic breast cancers were established by subcutaneous inocula-
tion of 4T1 cells. Briefly, 1 × 106 4T1 cells were injected subcutaneously
in the right flank of BALB/c mice. At day 6 after tumor inoculation
(tumors reached an average diameter of 5 mm), animals were randomly
assigned to four groups and treated with vehicle, rapamycin (4 mg/kg),
sunitinib (10 mg/kg), and rapamycin (4 mg/kg) and sunitinib (10
mg/kg), respectively. Sunitinib was administered daily by gavage,
and rapamycin was intraperitoneally administered daily. Tumor
diameters were measured with a caliper, and tumor volumes were
calculated as previously reported [21]. Tumor burden was
measured by the tumor volume and the gross wet weight of
tumors. Metastatic and disseminated tumors were assessed by
gross evaluation and microscopical examination.
Histopathologic Examination and Hypoxia Assessment
At 21-day posttreatment, tumor was harvested, fixed, and
embedded in paraffin. Tumor sections were stained with CD31
(Abcam, Cambridge, UK) and counterstained with hematoxylin
(Beyotime, Jiangsu, China). Liver and kidney metastases wereevaluated on hematoxylin and eosin (H&E)-stained sections.
Twenty-one days after treatment, tumor-bearing mice were injected
intraperitoneally with the hypoxic cell marker Hypoxyprobe-1
(60 mg/kg; Hypoxyprobe™-1, HPI Inc., Burlington, MA) and killed
90 minutes later. Tumors were excised, and frozen tumor sections
were prepared. Tumor sections were stained with fluorescein
isothiocyanate–conjugated mouse anti–Hypoxyprobe-1 monoclonal
antibody (1:100) at 37°C for 1 hour. The hypoxic tissues were
examined under a fluorescence microscope.
Flow Cytometry
At day 21 of posttreatment, spleens were harvested, and
erythrocytes were lysed. Spleen cells were centrifuged, washed with
phosphate-buffered saline, and then incubated with CD11b-
peridinin chlorophyll protein(PerCP)-Cy5.5 Gr-1–phycoerythrin
(PE) antibodies (BD Pharmingen, San Diego, CA) for 30 minutes
at 4°C. Single-cell suspension of lung cells of tumor-bearing mouse
was prepared and then stained with CD11b-PerCP-Cy5.5, Gr-1–PE
antibodies (BD Pharmingen) for 30 minutes at 4°C. For flow
cytometry analysis, cells were acquired with FACSCalibur flow
cytometer and analyzed with CellQuest software (BD Biosciences,
San Jose, CA).
Reverse Transcription–Polymerase Chain Reaction
Total RNA was isolated from tumor tissues using an RNA isolation
kit (Axygen, Union City, CA, AP-MN-MS-RNA-50) and reverse
transcribed (Takara Bio Inc., Otsu, Japan, RR047A) following the
manufacturer’s protocols. Polymerase chain reaction (PCR) was
performed on a CFX 96 real-time PCR thermocycler (Bio-Rad
Laboratories, Hercules, CA) using specific primers and SYBR Premix
Ex Taq II (Takara Bio Inc., Otsu, Japan, RR820A). Primer pairs are as
follows: mouse 18S RNA, forward—CGCCGCTAGAGGT-
GAAATTCT and reverse—CGAACCTCCGACTTTCGTTCT;
mouse interleukin-10 (IL-10), forward—ACCTGCTCCACTGCCT
TGCT and reverse—GGTTGCCAAGCCTTATCGGA;mouse IL-6,
forward—GATGGATGCTACCAAACTGGAT and reverse—
CCAGGTAGCTATGGTACTCCAGA; mouse arginase 1, forward
—GCTGTCTTCCCAAGAGTTGGG and reverse—ATGGAAGA-
GACCTTCAGCTAC; mouse indoleamine 2,3-dioxygenase (IDO),
forward—TGGGACATTCCTTCAGTGGC and reverse—
TCTCGAAGCTGCCCGTTCT; mouse transforming growth factor
β (TGF-β), forward—CTCCCGTGGCTTCTAGTGC and reverse—
GCCTTAGTTTGGACAGGATCTG. Data from the real-time PCR
reactions were analyzed using CFX Manager Software 2.1 (Bio-
Rad Laboratories). Relative changes of mRNA expression were analyzed
with the 2–△△Ct method, with 18S RNA serving as an internal
reference. These standardized data were used to calculate fold changes in
gene expression. All real-time PCR amplifications were performed
in triplicate.
ELISA
ELISA assay was performed on serum samples taken 21 days post-
therapy to determine levels of IL-6 and TGF-β protein in the
circulation. Briefly, 96-well microtiter plates (MultiSciences, Hang
zhou, China, Catalog No. EK2812; EK2062) were coated with serum
from tumor-bearing mouse for 2 hours at 37°C. For TGF-β, serum
was acidified with 1 N HCl and then neutralized with 1 N
NaOH. Biotinylated secondary antibody was then added to the
plates for 1 hour at 37°C. Finally, streptavidin conjugated to HRP
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achieved using tetramethylbenzidine (TMB) (MultiSciences, Hang
zhou, China) solution for 10 to 15 minutes and then stopped.
Optical density was measured at 450 nm. The concentration of
IL-6 and TGF-β was calculated by comparison to the standard
curve.
Statistical Analysis
Comparisons between groups were analyzed by means of one-
way analysis of variance. A value of P b .05 was designated as
statistical significance.
Results
The Combination of Rapamycin and Sunitinib Retarded
Tumor Growth
The synergistic antitumor effect of rapamycin and sunitinib on
tumor growth was evaluated. Subcutaneous implantation of 4T1
breast cancer cells resulted in large tumors in the untreated group, and
the mean tumor volume was 1157.02 ± 138.59 mm3 21 days after
implantation. There was limited tumor growth in mice treated with
sunitinib alone. Rapamycin monotherapy also significantly reduced
the tumor growth. The combination treatment induced a robust
delay in tumor growth, with the tumor volume only 357.81 ± 64.14
mm3 (Figure 1, A and B). As expected, the combination group had
the lowest tumor weight (Figure 1C). In addition, the combinational
strategy reduced splenomegaly in 4T1 breast cancer models
(Figure 1D). Together, these data suggested that this combinational
strategy was effective to retard tumor progression in animal breast
tumor models.Figure 1. Combination of sunitinib and rapamycin retarded tumor gro
weight (C) of 4T1 tumors treated with vehicle, sunitinib, rapamycin
significantly reduced the splenomegaly in tumor-bearing mouse (D).*Combination Treatment Reduced Tumor Vessel Density
To determine the effect of combinational therapy on the tumor
vessel density in tumor microenvironment, immunostaining against
CD31 was performed. Compared with other groups, tumors in the
vehicle group had the most vasculature, with large and tortuous
morphology. The combinational strategy could robustly reduce
the blood vessel density in the tumor microenvironment (Figure 2, A
and B). Though rapamycin or sunitinib monotherapy could also
inhibit the microvessle density, both were weaker than the
combination treatment (Figure 2, A and B).
Combination Therapy Reduced Myeloid-Derived Suppressor
Cells in the Spleen
Myeloid-derived suppressor cells (MDSCs) have been shown
contributing to tumor progression through immunosuppression and
proangiogenesis. The quantity of MDSCs in the spleen was assessed
with flow cytometry.On the 21 days of post-therapy, more than 50%of
MDSCs were observed in the vehicle-treated group (Figure 3, A and B).
However, there was only slightly reduction ofMDSCs, but no statistical
significance was observed in both sunitinib and rapamycin groups.
Compared with other groups, combination treatment substantially
reduced theMDSCs, and there was less than 30%MDSCs in the spleen
(Figure 3, A and B). Together, the combinational strategy significantly
decreased MDSC proportion in the spleen.
Antiangiogenic Therapy Promoted Lung Metastasis
To determine whether the combined therapy reduced the cancer
metastasis, we examined the metastasis macroscopically and micro-
scopically. Unexpectedly, though the combination of sunitinib andwth. Tumor growth curve (A), representative images (B), and tumor
, and sunitinib and rapamycin, respectively. Combination therapy
P b .01 versus vehicle and #P b .05 versus vehicle.
Figure 2. Reduced microvessel density in the tumor microenvironment. (A) Immunohistochemical stain against CD31 was performed to
evaluate the blood vessels in tumor sections. Control group showed large and tortuous blood vessels. (B) Combinational strategy and
monothertapy with sunitinib and rapamycin robustly reduced the blood vessel density. * P b .05 versus vehicle.
224 Antiangiogenesis Promotes Metastasis Yin et al. Translational Oncology Vol. 7, No. 2, 2014rapamycin retarded the tumor growth, it also promoted lung
metastasis. The enhanced metastasis was assessed on the day-21 of
post-therapy by gross evaluation (Figure 4A) and further confirmed
by the microscopical examination (Figure 4B). There was apparent
lung metastasis in both rapamycin monotherapy and the combination
group more lung metastasis was observed in the combination group
(Figure 4C). These data indicated that rapamycin could induce
metastasis in cancer therapy and make it more severe once combined
with antiangiogenic therapy.
Antiangiogenic Therapy Exaggerated Hypoxia
To investigate the possible mechanism of metastasis induced by the
combination therapy, immunohistochemistry of pimonidazole(Hypoxyprobe™-1, HPI Inc., Burlington, MA) adducts for hypoxic
cells was evaluated in tumor sections. The results showed that
significantly larger hypoxic areas exist in the tumors after antiangio-
genic therapy with sunitinib or rapamycin compared with the control
group (Figure 5).
Rapamycin InducedVersicanExpression and Immunosuppression
in Lung Tissue
Versican secreted by MDSCs has been shown to accelerate lung
metastasis. To investigate whether versican participates in rapamy-
cin and sunitnib–induced lung metastasis, we examined the
versican levels in the lungs with reverse transcription–PCR (RT-
PCR) assay. Rapamycin markedly upregulated versican expression
Figure 3. Reduced MDSCs in spleens. (A) Twenty-one days posttreatment, the quantity of MDSCs in the spleen of tumor-bearing mice
was evaluated by flow cytometry. (B) Monothertapy with sunitinib or rapamycin did not reduce the MDSCs, whereas combinational
strategy significantly reduced the MDSCs in the spleen. * P b .05 versus vehicle, sunitinib, and rapamycin.
Figure 4. Combination of sunitinib and rapamycin promoted tumor lungmetastasis. (A) Lungs of tumor-bearing mice were harvested, and
the metastatic nodules were grossly evaluated. (B) H&E stain showed microscopically the metastatic foci in lung sections. (C) Sunitinib
combined with rapamycin promoted tumor lung metastasis. *P b .01 versus vehicle and #P b .05 versus vehicle.
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Figure 5. Antiangiogenic therapy exaggerated hypoxia. Immunohistochemistry of pimonidazole adducts for hypoxic cells was
evaluated in tumor sections. Larger hypoxic areas existed in the tumor microenvironment after antiangiogenic therapy with sunitinib
or/and rapamycin.
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(Figure 6A). We then assessed whether the increased versican was
due to increased MDSCs in the lungs. Unexpectedly, MDSCs were
decreased in the combination group (Figure 6B), which suggested
other sources of versican.
Next, we evaluated the immunosuppressive molecules and
cytokines in the lungs of tumor-bearing mouse. Arginase 1, IDO,
and IL-6 expression in the lungs was increased after treatment with
rapamycin alone or together with sunitinib (Figure 6C). Sunitinib
alone was not sufficient to induce arginase 1, IDO, and IL-6, in
which it induced more TGF-β and IL-10, two other immunosup-
pressive cytokines. Rapamycin also significantly increased TGF-β and
IL-10 expression in the lungs, whereas the combination of two drugs
only induced TGF-β expression but not IL-10 (Figure 6C).
We further examined those molecules in the tumor tissues. Both
sunitinib and rapamycin could decrease IL-10 in the tumor
microenvironment but not arginase 1 (Figure 6D). Rapamycin
significantly reduced IDO levels in the tumor (Figure 6D), which was
controversial to that in lungs. IL-6 and TGF- β in the lungs were
obviously increased in the lung tissues, and we then evaluated the
systemic levels of those two cytokines. Antiangiogenic therapy with
two drugs reduced TGF- β whereas it markedly elevated IL-6 levels in
the blood (Figure 6E). Collectively, those results indicated thatsunitinib and rapamycin induced an immunosuppressive microenvi-
ronment in the metastatic sites but not in the primary tumor site.
Combinational Therapy Did Not Promote Distal Metastasis in
Liver and Kidney
To investigate whether rapamycin promotes cancer dissemination,
important organs of tumor-bearing mice were examined. No
metastatic nodule was detected macroscopically in the liver and
kidney in the tumor models. In addition, we also examined the
histology of livers and kidneys, and no metastasis was detected (data
not shown). Those results suggested that, though rapamycin and
sunitinib promoted lung metastasis, it did not cause the dissemina-
tion of cancer cells to other important organs.Discussion
Angiogenesis is pivotal for tumor growth and metastasis [1,22].
Antiangiogenic therapy has been designated as an effective way for
cancer treatment [2]. However, a plethora of reports shows that
antiangiogenic therapy can induce metastasis [3]. In our study, the
combination of rapamycin and sunitinib hampered tumor growth,
reduced splenomegaly and tumor microvessel density, and decreased
MDSCs in the spleen. However, we found that mTOR inhibitor did
not solve the problem of metastasis induced by antiangiogenic
Figure 6. Rapamycin induced versican expression and immunosuppression in lung tissue. (A) Versican expression was evaluated with RT-
PCR after antiangiogenic treatment. Rapamycin-based therapy increased versican expression in the metastatic lung tissue. (B) Flow
cytometry was performed to detect MDSCs in the lungs. The combinational therapy reduced MDSCs in the lungs. (C) The expression of
IL-6, IDO, arginase 1, TGF-β, and IL-10 in the lung tissue was evaluated with RT-PCR. (D) The expression of IDO, arginase 1, and IL-10 in the
tumor tissue was evaluated with RT-PCR. (E) The circulation levels of IL-6 and TGF-β were examined with ELISA. *P b .01 versus vehicle
and #P b .05 versus vehicle.
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by antiangiogenic therapy.
mTOR regulates many basic cellular behavior, such as
proliferation, survival, protein synthesis, and angiogenesis. Target-
ing the PI3K/Akt/mTOR pathway is a promising concept for
cancer therapy. Rapamycin forms a complex with a conserved
receptor FK506-binding protein 12 and then binds to mTOR, and
the interaction then causes inactivation of p70S6 kinase [19].Rapamycin inhibits albumin-induced epithelial-to-mesenchymal
transition in the renal diseases [23]. Rapamycin also increases E-
cadherin expression in renal cancer cells and converts the invasive
to a noninvasive phenotype. Through disruption of the mTORC2
assembly and down-regulation of phosphorylated signal transducer
and activator of transcription-3 (S727), rapamycin downregulates
Twist1 and matrix metalloproteinase-2 expression and then
suppresses the motility and the peritoneal dissemination of
228 Antiangiogenesis Promotes Metastasis Yin et al. Translational Oncology Vol. 7, No. 2, 2014tumor cells [24]. Inhibitor of mTOR has achieved promising
results in the clinical trials [25]. Rapamycin-based mTOR
inhibition decreases angiogenesis in several tumor types [16,18].
In our present study, we demonstrated that rapamycin and
sunitinib can synergistically reduce tumor microvessel density.
In tumor-bearing hosts, MDSCs accumulate in the central and
periphery lymph organ, blood, and tumor sites. MDSCs contribute
to tumor progression through exerting immunosuppressive effects
and promote angiogenesis in tumor microenvironment [26].
Myeloid cells treated with rapamycin could produce more IL-12
and less IL-10 [27]. Rapamycin could skew toward a proinflamma-
tory T helper 1 pattern [27]. We found that combination can
significantly reduce the splenomagly and MDSC accumulation in
the spleen, which suggested that our combination strategy may
inhibit the immunosuppression induced by MDSCs. However, in
our study, we did not detect the decrease of MDSC in sunitinib or
rapamycin therapy 21 days after treatment.
Recent report shows that mTOR promotes cancer cell migration
and invasion [13]. In our present study, we did not detect the
hypothesized synergistic therapeutic effect of combination of
sunitinib and rapamycin on tumor metastasis. Sunitinib can slightly
increase the metastasis. Rapamycin can induce robust lung metastasis
of 4T1 tumors, which is assistant to the recent report, which
demonstrates that mTOR inhibitor RAD001 (Novartis, Basel,
Switzerland) results in the occurrence of distant metastasis [28].
Furthermore, more metastatic tumors were observed in the
combination group. We also examined the liver and kidney and did
not detect the metastasis in the liver and kidney in our tumor models.
We observed the exaggerated hypoxia after antiangiogenic therapy.
The acceleration of lung metastasis could be caused by treatment-
induced hypoxia. Hypoxia has been designated as the major triggering
factor for tumor metastasis. The molecular pathways regulated by
hypoxia steel tumor cells to generate functionally abnormal tumor
vessels through pathologic angiogenesis and recruitment of bone
marrow–derived and regulatory T cells [29].
Versican is an extracellular matrix proteoglycan that stimulates
mesenchymal-to-epithelial transition of metastatic cancer cells and
accelerates lung metastases [30]. Elevated versican expression is also
found within the metastatic lung of patients with breast cancer [30].
We evaluated versican levels in the lungs after sunitinib and
rapamycin therapy. Sunitinib is not sufficient to induce versican
expression. Rapamycin strongly increased expression of versican, and
the combinational therapy had the highest versican levels. Versican in
metastatic lungs was mainly attributed to the MDSCs [30]. We found
that, however, combination therapy with sunitinib plus rapamycin
reduced MDSCs in the lung tissues, which may indicate that MDSCs
are not the main source of versican.
We also evaluated the immunosuppressive molecules in the lungs
after antiangiogenic therapy with sunitinib and rapamycin. Arginase
1, IDO, and IL-6 expression in the lungs was increased after
rapamycin or combinational therapy. Though insufficient to induce
arginase 1, IDO, and IL-6, sunitinib induced more TGF-β and IL-10
in the lungs of tumor-bearing mice. Interestingly, in the tumor
microenvironment, we detected less IDO and IL-10 expression after
rapamycin-based therapy. Antiangiogenic therapy with those two
drugs reduced TGF- β whereas it markedly induced IL-6 levels in the
blood. Thus, we postulate that antiangiogenic therapy with sunitinib
and rapamycin results in an immunosuppressive microenvironment
in the metastatic sites and then accelerates lung metastasis.In conclusion, though rapamycin and sunitinib could synergisti-
cally reduce tumor volume, the combination therapy exacerbated
tumor metastasis. Our findings warrant that further mTOR
inhibition treatment should be closely watched in clinical setting,
especially when combined with other antiangiogenic therapy.References
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